BCTXZ BriaCell Therapeutics Corp. War
$0.14▼ -3.57%
Healthcare
Other
Volume 10.5K
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.13 - 0.15
% vs 50 MA
-20.21%
% vs 200 MA
–%
RSI-14
43.2
MACD Histogram
-0.0100
Beta (1Y vs SPY)
-0.11
Free Cash Flow
-$7.15M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$7.43M
COGS
–
Operating Exp
$7.62M
Operating Income
-$7.62M
EBIT
-$7.62M
Pretax Income
-$7.24M
Net Income
-$7.16M
Price & Volume History
Loading chart…
Recent News
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
GlobeNewswire · Oct 23, 2026 7:30 AM ET
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
GlobeNewswire · Oct 6, 2026 7:30 AM ET
BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone
InvestorsHub · Aug 24, 2026 8:47 AM ET
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
GlobeNewswire · Aug 24, 2026 7:30 AM ET
BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study
MT Newswires · Aug 5, 2026 3:03 PM ET
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
GlobeNewswire · Aug 5, 2026 7:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See BCTXZ's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.